Lobbying Information
Subject Matters
- Budget
- Economic Development
- Government Procurement
- Health
- Industry
- Intellectual Property
- International Relations
- International Trade
- Science and Technology
Subject Matter Details
Policies or Program
- An opportunity for a multi-stakeholder approach in developing a solution for childhood diarrhea in low to middle income countries.
- Health Canada regarding the development and implementation of an approval pathway for Subsequent Entry Biologics (SEBs), Biologics and Specialty Products.
- Health Canada regarding the modernization of the Food and Drug Act (formerly Bill C-51) with respect to the development and implementation of a Progressive Licensing Framework for pharmaceuticals
- Health Canada's consultation on pain medicines.
- Innovation, Science and Economic Development Canada. Science and Technology strategy regarding the need for a balanced Intellectual Property regime and the important role competition plays in encouraging innovation.
- International Trade regarding intellectual property provisions in bilateral and multilateral trade agreements.
- Providing input into creating a more resilient pharmaceutical supply chain with increased supply redundancy by supporting a coordinated approach to establish a list of high priority/essential medicines for potential government procurement.
Regulation
- Innovation, Science and Economic Development Canada regarding the need to restore balance to the Patented Medicines (Notice of Compliance) Regulations with respect to pharmaceuticals and address operational concerns including: lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Canadian Heritage (PCH)
-
Environment and Climate Change Canada (ECCC)
-
Finance Canada (FIN)
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Immigration, Refugees and Citizenship Canada (IRCC)
-
Immigration and Refugee Board (IRB)
-
Innovation, Science and Economic Development Canada (ISED)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Senate of Canada
In-house Corporation Details
Description of activities
PHARMACEUTICAL COMPANY
Manufacturing and distribution of Generic Prescription Pharmaceuticals Products
Responsible officer name and position during the period of this registration
Christine Poulin,
Senior Vice President and General Manager
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
30 Novopharm Court
Toronto, ON M1B 2K9
Canada
Telephone number:
416-940-6767
Parent Company Information
- Teva
-
5 Basel St.
Petach Tikva 49131
Israel
Subsidiary Beneficiary Information
Teva Canada Limited / Teva Canada Limitee does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Terry Creighton,
VP Global Public Policy |
No public offices held
- Benjamin Gray,
Vice President & General Counsel |
No public offices held
- Robert Kulik,
Director, Government Affairs |
No public offices held
- Mathi Mathivanan,
Sr Director Regulatory Affairs, Regulatory Affairs |
No public offices held
- Christine Poulin,
Senior VP & GM, Teva Canada Limited |
No public offices held
- Chander Sehgal,
Assoc. Director, Market Access |
No public offices held
- Jason Soler,
Director, Market Access |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
No lobbyists added